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(J Thorac Oncol. 2008;3: 682–683)
We report the unusual case of an 81-year-old man withsmall cell lung cancer and metastases to adrenal gland
who underwent surgical resection of adrenal metastasis 5
years after original diagnosis. He remains continuously dis-
ease-free for 66 months after metastatic disease resection.
He did not receive any preoperative or postoperative chemo-
therapy.
CASE REPORT
Patient is an 81-year-old Caucasian gentleman who was
diagnosed with limited stage small cell lung cancer in 1997
with possible abnormality in left adrenal gland at that time.
He received seven courses of chemotherapy with cisplatin
plus etoposide and achieved a clinical complete remission.
Patient did not receive any radiotherapy or prophylactic
cranial irradiation for his disease. He remained progression
free until 5 years later, when in 2002 he developed significant
fatigue and iron deficiency anemia with a hemoglobin of 5
g/dl. A colonoscopy revealed a poorly differentiated adeno-
carcinoma of the cecum. Subsequent staging abdominal com-
puted tomography scan revealed an 8-cm left adrenal mass
which was biopsied and read as metastatic small cell lung
cancer. Patient was referred to surgical oncologist and under-
went right hemicolectomy as well as simultaneous left adre-
nalectomy. He had seven positive lymph nodes from his cecal
adenocarcinoma. The resected adrenal mass confirmed met-
astatic small cell lung cancer (Figure 1).
Patient’s postoperative course was marked with slow
recovery resulting in decision to forego any consideration for
adjuvant chemotherapy for either his stage III cecal carci-
noma or his small cell lung cancer.
Patient demonstrates no evidence of progressive dis-
ease with normal history and physicals, complete blood
counts, chest x-ray, and colonoscopy, 64 months after his
adrenalectomy. He has had no further problems from his
resected small cell lung cancer and remains continuously
disease-free 64 months from his adrenal metastatic resec-
tion. He also remains disease free from his colon cancer after
resection.
DISCUSSION
Lung cancer accounts for 15% of all cancer diagnoses
with approximately 213,000 new cases annually.1 It remains
the leading cause of cancer related mortality with 160,000
deaths each year.1 Small cell lung cancer (SCLC) accounts
for 13% of all lung cancer cases affecting approximately
27,000 patients annually.1 SCLC is a chemotherapy-radio-
therapy sensitive disease, and limited SCLC is traditionally
treated with cisplatin or carboplatin with etoposide and con-
current chest radiation therapy.2,3 Surgery is usually not
considered in limited SCLC due to early hematogenous
dissemination. Nevertheless, the possible benefit of local
surgical resection has recently being assessed as part of
multimodality therapy in limited SCLC.4,5
Extensive SCLC is usually treated with a platinum
compound plus etoposide or irinotecan.6 Solitary or multiple
metastases receive the same chemotherapy.
Metastatectomy has been shown to improve survival in
isolated adrenal metastatic lesions in non-small cell lung
cancer.7,8 Utility of resection, for isolated metastasis in ex-
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FIGURE 1. Left adrenal mass showing metastatic small cell
lung cancer.
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tensive SCLC is dubious due to the basic biology of this
disease.
This patient had a sensitive relapse and would have
been expected to respond with either platinum or etoposide
chemotherapy. Metastatectomy was chosen because of the
need for emergent colon cancer resection. A combined pro-
cedure with hemicolectomy and left adrenalectomy was con-
sidered reasonable because of patient’s long disease-free
survival from SCLC and presence of solitary metastatic
lesion. To the best of our knowledge this case represents the
first long-term survival with resection of a metastatic lesion in
SCLC.
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